This is a signed agreement, not a completed transaction. Closing is expected by December 31, subject to regulatory approvals and customary conditions. The deal is expected to be financed mainly with debt, which matches company-linked reporting. One report described it as all-equity, but that description is inconsistent with the rest of the coverage and should be disregarded. STERIS will revise its fiscal 2027 outlook after closing. The size of that revision has not been disclosed.
For attorneys, the key items are the regulatory review and the tax-benefit assumption. The $300 million tax figure is a forecast, and it reduces the headline price by about one-seventh, so its treatment will matter in diligence and in any purchase-price dispute. STERIS has a tax-driven history: it was the first American company to agree a deal that lowered its tax burden by moving overseas after the Obama administration moved to curb that practice. That history is why the tax component is drawing attention. The 2028 earnout will also need careful drafting and tracking. The deal extends STERIS's push into operating-room consumables, and it follows an August 5 announcement, made by North Carolina Governor Josh Stein, of a planned $600 million manufacturing and distribution center in Sanford that will create 335 jobs in Lee County.